Systems biology for identification of molecular networks in multiple sclerosis

1 Satoh JI  Tabunoki H  Yamamura T  . Molecular network of the comprehensive multiple sclerosis brain-lesion proteome. Mult Scler 2009; 15: 531–541.

2 Villoslada P  , Steinman, L, Baranzini, S. Systems Biology and Its Application to the Understanding of Neurological Diseases. Annals of Neurology 2008 (in press).

3 Han MH  Hwang SI  Roy DB  . Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076–1081.

4 Steinman L  . Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5: 575–581.

5 Lock C  Hermans G  Pedotti R  . Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500–508.

6 Chabas D  Baranzini SE  Mitchell D  . The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731–1735.

7 Lassmann H  Bruck W  Lucchinetti C  . Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–1121.

8 Fernald GH  Knott S  Pachner A  . Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007; 178: 5076–5085.

9 Miller DH  Khan OA  Sheremata WA  . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

10 Polman CH  O’Connor PW  Havrdova E  . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

11 Steinman L  . Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4: 510–518.

12 Murugaiyan G  Mittal A  Weiner HL  . Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 2008; 181: 7480–7488.

13 Vogt MH  Floris S  Killestein J  . Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004; 155: 155–160.

14 Comabella M  Pericot I  Goertsches R  . Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158: 231–239.

15 Hur EM  Youssef S  Haws ME  Zhang SY  Sobel RA  Steinman L  . Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8: 74–83.

16 Youssef S  Steinman L  . At once harmful and beneficial: the dual properties of NF-kappaB. Nat Immunol 2006; 7: 901–902.

17 Singh RA  Zhang JZ  . Differential activation of ERK, p38, and JNK required for Th1 and Th2 deviation in myelin-reactive T cells induced by altered peptide ligand. J Immunol 2004; 173: 7299–7307.

18 Wu L  Han DK  . Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev Proteomics 2006; 3: 611–619.

19 Dunn SE  Youssef S  Goldstein MJ  . Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401–412.

20 Linker RA  Lee DH  Stangel M  Gold R  . Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother 2008; 8: 1683–1690.

21 Nobel D  . The music of life: Biology beyond the genome. Oxford University Press, USA; 2006.